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Abstract
Optimal treatment regimes (OTR) are individualised treatment assignment strategies
that identify a medical treatment as optimal given all background information available on
the individual. We discuss Bayes optimal treatment regimes estimated using a loss func-
tion defined on the bivariate distribution of dichotomous potential outcomes. The proposed
approach allows considering more general objectives for the OTR than maximization of an
expected outcome (e.g., survival probability) by taking into account, for example, unneces-
sary treatment burden. As a motivating example we consider the case of oropharynx cancer
treatment where unnecessary burden due to chemotherapy is to be avoided while maxi-
mizing survival chances. Assuming ignorable treatment assignment we describe Bayesian
inference about the OTR including a sensitivity analysis on the unobserved partial associ-
ation of the potential outcomes. We evaluate the methodology by simulations that apply
Bayesian parametric and more flexible non-parametric outcome models. The proposed OTR
for oropharynx cancer reduces the frequency of the more burdensome chemotherapy assign-
ment by approximately 75% without reducing the average survival probability. This regime
thus offers a strong increase in expected quality of life of patients.
1 Introduction
An important question in current research in personalised medicine is how to select the best
treatment based on all information available about the individual. This development is facili-
tated as researchers have access to increasingly large amounts of observational data from diverse
sources, such as electronic patient files or extracts from CT or MRI scans and genomics. Tra-
ditional analyses from evidence-based medicine often only use sub-group analysis of treatment
effects for predefined clinical baseline characteristics. Our motivating example is primary treat-
ment of oropharyngeal squamous cell carcinoma (OPSCC) that includes radiotherapy (RT) or
RT with concomitant chemotherapy (CRT). Meta-analyses have shown an average 6.5 %-points
gain in 5-year survival for patients given CRT as opposed to RT treatment, where survival gain
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Leemans, MD PhD, and R.H. Brakenhoff, PhD (Amsterdam UMC, Vrije Universiteit Amsterdam, Otolaryngology
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under CRT is higher in patients with high-stage tumours, better performance status, and the
younger (Pignon, Maître, Maillard, & Bourhis, 2009). These results suggest the potential of
simple individualised treatment rules (e.g., give CRT in high-stage patients), but such statistics
are only available for a few characteristics and it is unknown how the available characteristics
interact. Another important consideration in practice is treatment burden that patients en-
counter due to side-effects and toxicity (e.g., CRT is seriously toxic). Toxic treatments should
only be administered if a clear benefit is expected (e.g., survival instead of death). A rele-
vant question therefore is whether unknown individualised OPSCC treatment rules exist that
increase patient benefit beyond current standard of care in terms of survival and burden.
Finding a set of treatment assignment rules that optimize benefit for all patients in a
population means estimating an ’optimal treatment regime’ (OTR; Robins, 2004; Murphy,
2003). There is increased effort to develop OTR estimation methodology, both for dynamic
(multiple decisions taken in sequence) and static (decisions taken at one point in time) regimes
(Zhang, Tsiatis, Laber, & Davidian, 2012, 2013; Zhang, Tsiatis, Davidian, Zhang, & Laber, 2012;
Zajonc, 2012; Zhang et al., 2013; Zhao, Zeng, Laber, & Kosorok, 2015; Xu, Müller, Wahed, &
Thall, 2016; Murray, Yuan, & Thall, 2017; Thall, Wooten, Logothetis, Millikan, & Tannir,
2007). This literature assumes that data from a randomized trial are available or that data are
observational and treatment assignment is ignorable (Rubin, 1978). Regardless of type of study
design, the risk of misspecifying the outcome model is a substantial concern because it leads to
biased estimates of treatment effects and incorrect treatment decisions. A viable approach is,
therefore, to deploy statistical and machine learning techniques to approximate the unknown
functional relationship between potential outcomes and patient characteristics (Qian & Murphy,
2011; Taylor, Cheng, & Foster, 2015; Imai & Ratkovic, 2013; Xu et al., 2016; Murray et al., 2017;
Athey & Imbens, 2016). An alternative is to use treatment assignment propensities in weighted
estimating equations or treatment assignment classifiers (Robins, Orellana, & Rotnitzky, 2008;
Zhang, Tsiatis, Davidian, et al., 2012; Zhao, Zeng, Rush, & Kosorok, 2012; Zhao et al., 2015).
These procedures require correct specification of the treatment assignment model (or known
propensities), if the outcome model is misspecified.
In this paper, we consider Bayesian estimation of static OTR for dichotomous potential
outcomes with observational data and develop an OTR for OPSCC treatment. Our paper
extends available OTR methodology in two respects. First, we implement a Bayesian decision
theoretical framework using a general loss function defined on the bivariate distribution of the
potential outcomes (for Bayesian decision theory see Parmigiani & Inoue, 2009). We select the
treatment which minimizes the mean posterior loss (the Bayes decision). This is important,
because loss may be related to a patient covariate even in the absence of a treatment-covariate
interaction effect in, for instance, a logistic regression. We introduce the so-called conditional
parametrization of the loss function which allows penalizing three clinically relevant treatment
errors: (a) a more burdensome treatment is selected although the less burdensome one leads
to the same outcome (patient has unnecessary burden); (b) a less burdensome treatment is
selected but the patient only has positive outcome (e.g., survival) under the more burdensome
one (patient death is avoidable); (c) a more burdensome treatment is selected but the patient
only survives under the less burdensome one (avoidable death and unnecessary burden). Using
this approach with loss penalties for the unnecessary burden of CRT, we estimate an OTR for
OPSCC that strongly reduces CRT assignment by approximately 75% while holding average
three-year survival probabilities constant at the level of the observed regime. Our approach is
related to work by Li, Bekele, Ji, and Cook (2008) and Lee, Thall, Ji, and Müller (2015) who
defined utilities on a joint distribution of efficacy and toxicity in the design of dose-response
trials. Although similar in spirit, our focus is estimating OTR using a loss function that fully
depends on the distribution of potential (efficacy) outcomes.
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Second, we quantify uncertainty about the correctness of treatment decisions and the ex-
pected loss under the OTR. This objective is hard for much OTR methodology, but facilitated
in the Bayesian setting. Specifically, we are concerned with three sources of uncertainty in ob-
servational data, i.e. (i) sampling error, (ii) missing potential outcomes (Rubin, 2005), and (iii)
an unidentified partial correlation between the potential outcomes (Ding & Dasgupta, 2016).
Bayesian estimation facilitates quantifying uncertainty, because posterior distributions widen
in sparse regions of the data (due to i and ii) and unidentified parameters (iii) can be handled
in estimation. The potential for Bayesian inference about OTR has been recently recognized
by a small body of literature (Murray et al., 2017; Zajonc, 2012; Xu et al., 2016; Arjas &
Saarela, 2010; Thall et al., 2007). To avoid outcome model misspecification, we follow Murray
et al. (2017) and Xu et al. (2016) who use flexible non-parametric Bayesian learning techniques
for function approximation, in particular Bayesian additive regression trees (BART, Chipman,
George, & McCulloch, 2010; Hill, 2011). We develop a posterior estimate of certainty on the
optimal decision similar to Murray et al. (2017) and previously unconsidered credible intervals
of the expected loss and outcome under the OTR. We take into account the non-identified
partial correlation (iii) by a Bayesian sensitivity analysis. We caution that the selection of the
optimal treatment can distort the nominal frequentist coverage property of credible intervals,
because the optimal decision selects the posterior distribution of expected loss with the smaller
mean. Bounds on the type I error rate are derived.
The remainder of this paper is structured as follows. In section 2 we present the Bayesian
decision theoretical framework for OTR with discrete outcomes. In section 3 we discuss Bayesian
estimation and inference on the OTR using data from observational designs. In section 4 we
present results on a simulation study assessing performance of the estimation approach. Section
5 presents the application to treatment of OPSCC.
2 Theoretical framework
We consider observational data generated according to the Rubin causal model (Rubin, 1978,
1974). For two treatments, random variableW ∈ {0, 1} denotes assignment to treatment 0 or 1.
The observable potential outcomes are binary coded Y = (Y (0), Y (1)), with Y (1) the outcome
under W = 1 and Y (0) the outcome under W = 0. Depending on W either Y (0) or Y (1) is
observed, where the observed outcome is Y (W ) = WY (1) + (1−W )Y (0). Covariates X ∈ Rp
are observed pre-treatment measurements of confounders and predictors of (Y (0), Y (1)). We
assume for any observation that the potential outcomes are jointly multinomial distributed,
(Y (0), Y (1)|X) ∼ multinom(θ00, θ10, θ01, θ11|X, n = 1), (1)
with random parameter vector θ = (θ00, θ10, θ01, θ11). The marginal distributions are Bernoulli
with (Y (0)|X) ∼ Bern(θ1+|X) and (Y (1)|X) ∼ Bern(θ+1|X) with θ1+ := θ10 + θ11 and θ+1 :=
θ01 + θ11 where P (Y (0) = 1|X,θ) = E(Y (0)|X,θ) = E(Y (0)|X, θ1+) and P (Y (1) = 1|X,θ) =
E(Y (1)|X,θ) = E(Y (1)|X, θ+1).
In line with the Rubin causal model, we assume, first, ignorable treatment assignment
(Rubin, 1978),
Y (0), Y (1),θ ⊥ W |X (2)
meaning that the treatment assignment is conditionally independent of the potential outcomes
given patient covariates. In randomized trials Y (0), Y (1),θ ⊥ W holds unconditional X due
to randomization of W . Second, we assume positivity (overlap assumption) 0 < P (W |X) < 1,
which precludes deterministic treatment assignment. Third, we assume no interference between
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the treatment assignment of a patient and the outcomes of others (Stable Unit Treatment Value
Assumption (SUTVA), Imbens & Rubin, 2015). Due to SUTVA all observations are identically
and independently distributed according to the joint distribution of (Y (0), Y (1),W,X). The
complete data are D = {Y (0), Y (1),W,X}; the observed data are Dobs = {Y (W ),W,X}.
2.1 General loss function and Bayes decision
We introduce treatment decision a ∈ {0, 1} for any future patient with outcomes (Y (0), Y (1)),
where a = 0 denotes assigning treatment 0 and a = 1 assigning treatment 1. When a is assigned,
the observed outcome is Y (a) = (1 − a)Y (0) + aY (1). Without loss of generality we assume
that Y (a) = 1 denotes treatment success (e.g., survival) and Y (a) = 0 denotes treatment failure
(e.g., death). The loss associated with the treatment decision is described by a loss function:
L(Y (0), Y (1), a) :=
∑
(j,k)∈{0,1}2
L
(a)
jk 1{Y (0)=j,Y (1)=k} (3)
with L(a)jk ≥ 0 fixed loss coefficients. Our objective is to take a Bayes optimal treatment decision
for each new patient with profile X = x given a specific choice for L(a)jk . We define the expected
loss for a particular value of (θ, x) and decision a as
µL(a,θ,x) := EY |x,θ
[
L(Y (0), Y (1), a)
]
=
∑
(j,k)∈{0,1}2
L(Y (1) = j, Y (0) = k, a)P (Y (1) = j, Y (0) = k|x,θ) (4)
Parameter µL(a,θ,x) is the estimand on which optimal decisions are based and its uncertainty
is reflected by the posterior distribution across θ denoted pi(θ|x,D) where we condition on
X = x. We assume that sampling from pi(θ|x,D) is possible and defer details to section 3. The
Bayes decision a∗1(x) minimizes the posterior expected loss for X = x,
a∗1(x) := arg min
a
Eθ|x,D
[
µL(a,θ,x)
]
= arg min
a
∫
Θ
µL(a,θ,x)pi(θ|x,D)dθ (5)
with Θ the support of θ. We now define the loss contrast
∆L(θ,x) := µL(1,θ,x)− µL(0,θ,x), (6)
so that
a∗1(x) :=
{
1 if Eθ|x,D
[
∆L(θ,x)|x,D
]
< 0
0 else.
(7)
Parameter ∆L(θ,x) can be viewed as the conditional treatment effect on the expected loss and
its posterior density piθ|x,D(∆L(θ,x)|x,D) is a function of pi(θ|x,D). The posterior probability
ρ(x) that µL(1,θ,x) ≤ µL(0,θ,x) is
ρ(x) := P (∆L(θ,x) ≤ 0|x,D). (8)
Probability ρ(x) quantifies the posterior certainty about the treatment decision a∗1(x) = 1;
1 − ρ(x) may be used in the alternative case. It may be noted that ρ(x) can be used to form
an alternative decision rule
a∗2(x) :=
{
1 if ρ(x) > 0.5
0 else.
(9)
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This alternative uses the posterior median of piθ|x,D(∆L(θ,x)|x,D) instead of posterior mean
(7) and is Bayes for the 0− 1 loss function
L2(a2,θ,x) =
{
1 if (∆L(θ,x) > 0 ∩ a2 = 1) ∪ (∆L(θ,x) ≤ 0 ∩ a2 = 0)
0 else.
(10)
In the following, we write general a∗ and only index the parameter where needed. An OTR is
defined by a rule to compute a∗(x) and ρ(x) for any x sampled from p(X). The expected loss
(4) under the OTR is then given by µL(a∗(x),θ,x). A second relevant estimand is the expected
outcome under the OTR (e.g., survival probability). The expected outcome is
µY (a,θ,x) := EY |x,θ(Y (a)|x,θ) = (1− a)E(Y (0)|x, θ1+) + aE(Y (1)|x, θ+1), (11)
with µY (a∗(x),θ,x) under the OTR. This approach clearly distinguishes the expected loss and
the expected outcome, which are distinct target quantities.
2.2 Loss functions: two special cases
We discuss two important special cases of the fully parametrized loss function (3) (Table 1).
We now make the additional assumption that treatment decision a = 1 means administering
the treatment that is more burdensome, for instance, because of higher toxicity or more severe
side-effects (e.g., CRT). The ’marginal parametrization’ penalises a = 1 by Lt and it also
penalises a negative outcome (e.g., dying) under any treatment by Ld. This approach is akin to
making treatment decisions based on a quality-of-life adjusted outcome measure. The associated
contrast (6) simplifies to
∆L(θ,x) := Ld[E(Y (0)|x, θ1+)− E(Y (1)|x, θ+1)] + Lt, (12)
which now only depends on the marginal probabilities E(Y (0)|x, θ1+) and E(Y (1)|x, θ+1).
Table 1: Loss functions using the full, conditional, and marginal parametriza-
tions.
Full Conditional Marginal
Potential outcomes a = 0 a = 1 a = 0 a = 1 a = 0 a = 1
Y (0) = 0, Y (1) = 0 L(0)00 L
(1)
00 0 L
(1)
00 Ld Ld + Lt
Y (0) = 0, Y (1) = 1 L(0)01 L
(1)
01 L
(0)
01 0 Ld Lt
Y (0) = 1, Y (1) = 0 L(0)10 L
(1)
10 0 L
(1)
10 0 Ld + Lt
Y (0) = 1, Y (1) = 1 L(0)11 L
(1)
11 0 L
(1)
11 0 Lt
The ’conditional parametrization’ is a flexible generalization of the marginal parametriza-
tion. Losses are defined conditional on the potential outcome strata. In each stratum, the
wrong treatment decision is penalised whereas losses of the correct decisions are fixed at
zero. Two types of wrong decisions emerge. First, when the potential outcomes are equal,
(Y (0) = 0, Y (1) = 0) or (Y (0) = 1, Y (1) = 1), one should avoid giving the more burdensome
treatment (a = 1). Clearly, it is a central concern in practice to avoid unnecessary burden for
patients. The associated losses are L(1)00 and L
(1)
11 . Second, when the potential outcomes are not
equal, (Y (0) = 0, Y (1) = 1) or (Y (0) = 1, Y (1) = 0), taking the treatment decision leading
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to a negative outcome (e.g., death) is wrong (a = 0 or a = 1, respectively). The associated
parameters L(0)01 and L
(1)
10 encode the loss due to fatal treatment errors, because the alternative
treatment would have saved the patient. The parameters need not be equal. In particular, a
patient in stratum (Y (0) = 1, Y (1) = 0) with a = 1 not only receives the wrong treatment
but also encounters higher treatment burden than a patient in stratum (Y (0) = 0, Y (1) = 1)
with a = 0 (thus L(0)01 ≤ L(1)10 ). To the contrary, a patient in (Y (0) = 0, Y (1) = 1) correctly
receives a = 1 (and has burden) but now the burden is unavoidable, because the alternative
would be a negative outcome (e.g., death); hence L(1)01 = 0 here. In comparison, the marginal
parametrization assigns loss Lt irrespective of potential outcomes to decision a = 1, which in-
cludes (Y (0) = 0, Y (1) = 1); thus L(1)01 = Lt here. This loss is usually clinically irrelevant and
should not be attributed.
2.3 Regime maximizing the expected outcome
Let the decision a∗OTRmax(x) denote the regime maximizing the posterior expected outcome
(e.g., survival probability) with
a∗OTRmax(x) := arg max
a
∫
Θ
µY (a,θ,x)pi(θ|x,D)dθ (13)
=
{
1 if Eθ|x,D
[
∆Y (θ,x)|x,D
]
> 0
0 else,
(14)
with
∆Y (θ,x) := µY (1,θ,x)− µY (0,θ,x). (15)
This is the Bayesian equivalent to the frequentist approach for estimating OTR using an outcome
model (e.g. Zhang, Tsiatis, Davidian, et al., 2012). Regime (14) emerges as special case of the
conditional and marginal loss parametrization (Table 1) when minimization of loss in (5) equals
maximization of the expected outcome in (14). It can be shown that this situation emerges
for the conditional parametrization when L(0)01 = L
(1)
10 and L
(1)
00 = L
(1)
11 = 0. For the marginal
parametrization we have Lt = 0. In both cases, being indifferent about the more burdensome
treatment leads to maximizing the expected outcome; a plausible result that implies a trade-off
between minimizing expected loss (patient burden) and maximizing expected outcome (survival
probability).
3 Bayesian estimation
All estimands laid out in section 2.1 are functions of θ and X; hence our objective is to obtain
pi(θ|x,D). In practice, the bivariate distribution of (Y (0), Y (1)|X) in (1) is not identifiable by
the observed data Dobs = {Y (W ),W,X}. To address this problem, we first re-parametrize (1)
as
(Y (0), Y (1)|X) ∼ multinom(θ1+, θ+1, φ|X, n = 1), (16)
where φ := θ11θ00/(θ10θ01) is the partial odds ratio, i.e. the association of (Y (0), Y (1))
conditional on X. If φ = 1, θ11 = θ1+θ+1 so that θ10 = θ1+ − θ11, θ01 = θ+1 − θ11,
θ00 = 1 − θ11 − θ10 − θ01. If φ 6= 1, θ11 = −c2 + [(c2 − 4bd)(2b)−1]1/2 with b = 1 − φ, c =
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1− b(θ+1 + θ1+), d = −φθ+1θ1+ (Li et al., 2008). The posterior distribution of the parameters
in (16) then factors as (Ding & Li, 2018)
pi(θ1+, θ+1, φ|Y (0), Y (1),W,X) ∝ pi(θ1+, θ+1, φ|Y (W ),X) (17)
∝ pi(θ1+|Y (0),W = 0,X)pi(θ+1|Y (1),W = 1,X)p(φ), (18)
where (17) uses ignorable treatment assignment (2) and (18) assumes exchangeability and prior
independence. We see that the posterior pi(θ1+, θ+1, φ|D) only depends on the observed data
through the posteriors pi(θ1+|Y (0),W = 0,X) and pi(θ+1|Y (1),W = 1,X). A prior assumption
on the value or the distribution of φ then identifies pi(θ1+, θ+1, φ|D) and it enables a sensitivity
analysis as explained below. Note that the posterior of φ remains equal to its prior, because it is
not informed by the data. To arrive at pi(θ|x,D), Bayesian models are applied by specifying the
functional relationships of θ1+ and θ+1 with X. However, often no prior knowledge exists on the
correct functional form of models and prior distributions cannot be chosen informatively. We
then suggest applying non-parametric Bayesian function approximation using BART (Chipman
et al., 2010); see section 4. Posterior inference about µL(a∗(x),θ,x) and µY (a∗(x),θ,x), the
pointwise expected loss and outcome under the OTR, is possible. The posterior of µL is given
by
piθ|x,D(µL(a∗(x),θ,x)|x,D) =
{
piθ|x,D(µL(1,θ,x)|x,D) if a∗(x) = 1
piθ|x,D(µL(0,θ,x)|x,D) if a∗(x) = 0.
(19)
Given a∗(x), the posterior of µY , see (11), only depends on the marginal parameters
piθ|x,D(µY (a∗(x),θ,x)|x,D) =
{
piθ1+|x,D(µY (1, θ+1,x)|x,D) if a∗(x) = 1
piθ+1|x,D(µY (0, θ1+,x)|x,D) if a∗(x) = 0.
(20)
Point estimates are given by the posterior means and posterior (1− γ)-credible intervals can be
derived.
3.1 Frequentist coverage of credible intervals
The optimal treatment decision rule (7) selects a∗ for which the posterior mean is smallest.
Therefore, the posterior mean estimates and credible intervals may be biased by optimism. We
consider effects on frequentist coverage that optimism may have. Define the following (1− γ)-
credible interval for µL(1,θ,x):
I(1) = [Q(γ/2), Q(1− γ/2)],
where Q is the quantile function of the posterior distribution of µL(1,θ,x). Similarly, we define
a (1 − γ)-credible interval I(0) for µL(0,θ,x). Let I(a∗) be the interval corresponding to the
optimal treatment, i.e. we select either I(1) or I(0) based on the decision a∗.
To consider frequentist coverage, let θ0 be the true value of the parameter, i.e. the point at
which the posterior distribution of θ conditional on X = x contracts as the sample size tends
to infinity. Suppose that the coverage of I(1) for µL(1,θ0,x) is 1− α:
P (µL(1,θ0,x) < Q(γ/2)) = α/2, P (µL(1,θ0,x) > Q(1− γ/2)) = α/2, (21)
where P refers to the distribution of the expected posterior loss µL(1,θ,x) over repeated data
sets given a specific x. Similarly assume that I(0) has coverage 1−α for µL(0,θ0,x). We define
the coverage of I(a∗) for µL(a∗,θ0,x) as P (µL(a∗,θ0,x) ∈ I(a∗)).
The following theorem gives a crude lower bound on the coverage of I(a∗). It holds in
general and is similar in spirit to Bonferroni bounds.
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Theorem 1. Suppose the credible intervals I(1), I(0) have frequentist coverage 1−α. Then the
frequentist coverage of I(a∗) for µL(a∗,θ0,x) is at least 1− 2α.
For a proof see Appendix A. Under stricter conditions we now give a more detailed bound
on the coverage of I(a∗). It is shown that the coverage of I(a∗) can be equal to 1 − α despite
the optimism.
Theorem 2. Suppose the credible intervals I(1), I(0) have frequentist coverage 1 − α in the
sense of (21), suppose the distribution of the means of I(1), I(0) over repeated data sets is the
(correlated) bivariate normal distribution with variances σ2(1), σ2(0), and suppose the widths
of I(1), I(0) are constant over repeated data sets. Then the frequentist coverage of I(a∗) for
µL(a∗,θ0,x) is
(i) equal to 1− α, if µL(1,θ0,x) = µL(0,θ0,x) or σ2(1) = σ2(0),
(ii) strictly between 1 − α and 1 − 12α, if µL(1,θ0,x) > µL(0,θ0,x) and σ2(1) < σ2(0), or if
µL(1,θ0,x) < µL(0,θ0,x) and σ2(1) > σ2(0),
(iii) strictly between 1 − 32α and 1 − α, if µL(1,θ0,x) > µL(0,θ0,x) and σ2(1) > σ2(0), or if
µL(1,θ0,x) < µL(0,θ0,x) and σ2(1) < σ2(0).
For the proof of Theorem 2 see Appendix A. In particular, case (i) indicates that the
coverage is 1− α when there is no treatment effect (∆L) on the expected loss. From the proof
it follows that the bounds 1 − 12α and 1 − 32α in cases (ii) and (iii) are approximated only
for extreme values of the means and standard deviations. Therefore, Theorem 2 says that,
for reasonable values of the parameters and under the assumptions of the theorem, coverage is
approximately 1−α. In Section 4, we report on a simulation assessing the empirical performance
of the credible intervals under the OTR.
3.2 Sensitivity analysis
Inference may be sensitive to the non-identifiable parameter φ ∈ (0,∞) which denotes the
partial odds ratio between the potential outcomes. Prior assumptions on φ impact the joint
posterior pi(θ1+, θ+1, φ|D), (18), and thus pi(θ|D). The parameters affected by φ, however,
vary depending on the loss parametrization (Table 2). The marginal parametrization generally
leads to non-sensitive decisions a∗, a∗OTRmax and posteriors of µL and µY . For conditional loss,
decision a∗ (7) is sensitive to φ, as it depends on pi(θ|D). However, using the parametrization
OTRmax, decision a∗OTRmax only depends on the marginal probabilities, (15), so that it is non-
sensitive to φ. The posteriors of µL and µY generally depend on φ via a∗. Even when fixing
a∗ = a, the posterior of µL, (19), still depends on pi(θ|D). The posterior of µY , however, is
non-sensitive for fixed a∗ = a as it only depends on the marginal probabilities. These assertions
also hold for the posteriors of µL and µY under a∗OTRmax. For a sensitivity analysis, we use
a symmetric interval around reference φ0 (e.g., φ0 = 1) with conservative upper and lower
bounds [u, l]. Decisions a∗ are determined at φ = (l, φ0, u); a sensitive decision is affected by
the extreme choices [u, l]. For patients with sensitive decisions the optimal treatment decision
cannot be determined without an assumption on φ. For patients with non-sensitive decisions
we first take the optimal decision and then, holding the decision fixed at a = a∗, we define an
uniform prior on φ ∼ U(l, u), so that uncertainty in φ is reflected in the posterior of µL.
4 Simulation study
The objective of the simulation study was to evaluate the performance of the method in two
settings: (1) functional approximation of the marginal probabilities by Bayesian Additive Re-
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Table 2: Parameter sensitivity to partial correlation φ
by parametrizations.
Conditional Marginal
a∗(x) yes no
a∗OTRmax(x) no no
µL(a∗(x) = a,θ,x) yes no
µY (a∗(x) = a,θ,x) no no
µL(a∗OTRmax(x) = a,θ,x) yes no
µY (a∗OTRmax(x) = a,θ,x) no no
gression Trees (BART; Chipman et al., 2010) and (2) estimation by logistic regression models.
We evaluated effects on the
1. Accuracy of the Bayes decisions a∗1(x),
2. Bias of posterior mean estimates of expected loss and outcome under the OTR
(µL(a∗(x),θ,x) and µY (a∗(x),θ,x)), and
3. Interval width and frequentist coverage probability of credible intervals.
We considered the impact of five factors: the strength of heterogeneity in the treatment effects
∆Y (θ, X1) across a covariate X1, the strength of confounding in treatment assignment, sample
size, the type of loss function, and the presence of unrelated noise variables in X.
4.1 Simulation set-up
We first generated one variable X1 ∼ U(−1, 1) and specified the true outcome models as
E(Y (0)|X1;β0) = expit(β00 + β10X1 + β20X21 + β30X31 )
E(Y (1)|X1;β1) = expit(β01 + β11X1 + β21X21 + β31X31 ), (22)
with expit(x) = 1/(1 + exp(−x)) and βj = (β0j , β1j , β2j , β3j)T , j = 0, 1. Models (22) determine
the true conditional marginal probabilities (θ+1, θ1+)|X1; hence from (15) we have ∆Y (θ, X1) =
E(Y (1)|X1;β1)− E(Y (0)|X1;β0). We fixed β1 at β1 = (0.457, 3.185,−1.593,−2.124)T and set
β0 at β0 = (β01,−β11, β21,−β31)T (strong heterogeneity), β0 = (0.457, 1.343,−1.430,−1.217)T
(mild heterogeneity), or β0 = β1 (no heterogeneity). This choice for the parameters in (22)
leads to the realistic scenario of a biomarker impacting treatment success as shown in Figure
1a.
We simulated W from a Bernoulli distribution with success probability
E(W |X1;λ) = expit
(
λ(X1 − X¯1)
sd(X1)
)
(23)
where X¯1 and sd(X1) are sample mean and standard deviation. We chose λ ∈
{− log(3), 0, log(3)}, where λ = ± log(3) caused strong selectivity at the boundaries of the
support of X1 ∈ (−1, 1). Condition λ = 0 represented randomized assignment.
We considered two sets X, first, X = X1 and, second, X = (X1, X2, X3, X4, X5, X6),
where Xk ∼ U(−1, 1), k = 2, ..., 6, are independent noise variables unrelated to outcome and
9
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Figure 1: Illustration of simulation set-up and approximation with BART. (a) Marginal prob-
abilities for (Y (0), Y (1)) by degree of treatment effect heterogeneity, (b) approximation of the
marginal probability of Y (1) with BART, (c) estimated decision boundary at intersection of the
posterior means of losses, and (d) associated posterior probability ρ(X1). Figures (b)-(d) use
λ = − log(3) and n = 250 under strong treatment effect heterogeneity and OTR.25 loss.
treatment assignment; let q ∈ {0, 5} denote the number of noise variables. Furthermore, we
varied sample size n ∈ {250, 500, 1000} and considered two combinations of loss functions and
partial correlations in the conditional parametrization (Table 1), i.e. (L(1)00 , L
(0)
01 , L
(1)
10 , L
(1)
11 ) =
(0, 1, 1, 0) with φ = 1 and (0.25, 1, 1.25, 0.25) with φ = 5. The former parametrization leads to
OTRmax (14); the latter is referred to as OTR.25 in the following, where we penalised the loss
due to unnecessary burden by 25% of the loss of a wrong treatment decision. Let aopt denote
the optimal assignment rule determined on the marginal probabilities implied by true model
(22) and a loss function. Figures of the resulting true loss functions and optimal decisions
aopt for strong, mild, and no treatment effect heterogeneity are provided in Appendix B for
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both OTRmax and OTR.25. For the OTRmax regime maximizing expected outcome, (14), the
optimal decision boundary is also shown in Figure 1a. In particular, aoptOTRmax(X1) = 1{X1>0},
i.e. where ∆Y (θ, X1) > 0 the decision should be a = 1 for mild or strong heterogeneity and
a = 0 elsewhere. A special case emerges when β0 = β1 (no heterogeneity), i.e. choosing any
treatment has same marginal outcome probability (and loss) for any X1. Then infinitely many
optimal regimes aoptOTRmax(X1) exist. In this case, we chose a
opt
OTRmax = 0 as a benchmark to
compare Bayes decisions a∗1(X1) against.
4.2 Function approximation with BART
BART are flexible non-parametric function approximators with similarities to random forests
(Breiman, 2001) and gradient boosting (Friedman, 2001). However, BART offer the additional
advantage of inference on the posterior expected loss, posterior expected outcome, and the
posterior probability of a correct treatment decision. We illustrate decision taking with BART
in Figures 1b to 1d. Figure 1b shows approximation and credible intervals for E(Y (1)|X1;β1) for
a single data set in the simulation with λ = − log(3) and n = 250. Intervals widen in the sparse
region of (Y (1), X1) on the right, which is caused by selective treatment assignment. Figure 1c
shows true loss functions under a = 0, 1 for the OTR.25 condition and strong treatment effect
heterogeneity. The optimal decision boundary aoptOTR.25 is determined on the true losses and
Bayes decision a∗OTR.25 (7) is determined on the posterior means. For posterior probabilities
ρ(X1) (8) see Figure 1d. Close to the Bayes decision boundary there is higher uncertainty,
reflected by ρ close to 0.5.
For dichotomous outcomes Y , BART uses a probit sum-of-trees model consisting of
t = 1, ..., T separate regression trees g modelling latent variable Zi =
∑T
t=1 g(xi; Tt,Mt) + i,
where i ∼ N (0, 1) and Yi = 1{Zi>0}. Function g returns the leaf mean associated with obser-
vation xi, where Tt denotes a tree’s decision rules, and Mt = {ν1t, ..., νmt, ..., νMt} the vector
of M leaf node means. BART specifies prior distributions p(Tt) and p(νmt|Tt) regularizing
the depth of trees and the extremity of leave means to prevent BART from overfitting. Prior
p(Tt) assigns probability 1− κ(1 + δ)−η to the event that the node at depth δ is the end node
with defaults (κ = 0.95, η = 2) strongly favouring short trees with mode at δ = 2. Uni-
form priors are used for splitting variable assignment and splitting values. Prior p(νmt|Tt) is
N(0, σ2) with σ2 = 3k/
√
T effectively shrinking the leave means to zero to limit the influence
of the individual nodes on the overall fit (recommended k = 2). The posterior distribution
pi((T1,M1), ..., (TT ,MT )|Y ) is simulated using an MCMC backfitting algorithm with data aug-
mentation for Zi = Z (Chipman et al., 2010). Our implementation follows the procedure
described in section 3. We modelled observed Y (0) and Y (1) separately leading to two pos-
terior distributions pi((T1,M1), ..., (TT ,MT )|Y (0), X) and pi((T1,M1), ..., (TT ,MT )|Y (1), X).
For each draw from the posteriors, Z is obtained and evaluated at Φ(Z), where Φ is the cumu-
lative normal distribution, yielding samples from pi(θ1+|Y (0),X) and pi(θ+1|Y (1),X), respec-
tively.
4.3 Implementation
BART was implemented in R using pbart from package BART with settings k = 2, κ = 0.95,
η = 2, and T = 50, recommended by Chipman et al. (2010). We compared the performance
of BART to Bayesian logistic regression. Without noise variables in the set X = X1 (q = 0)
the models were (correctly) specified as in (22). With noise variables (q = 5), the models were
specified as E(Y (j)|X;βj) = expit(∑6k=1∑3p=1 βjkpXpk), j = 0, 1. In both cases, we imposed
an improper uniform prior, p(β0,β1) ∝ const. We used R function mcmclogit from package
MCMCpack with default settings, which implements a Metropolis algorithm to generate samples
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from the posterior of (β0,β1). We ran Monte Carlo simulations by generating K = 103 data
sets for each factorial combination of treatment effect heterogeneity in β0 (22), strength of
selection mechanism in λ (23), sample size n, loss function (OTRmax or OTR.25), and number
of independent noise variables (q) in X. For each data set we generated 5 × 103 samples
from the posterior distributions after 103 samples of burn-in. We then determined for all
observed xik, where i = 1, ...., n the observations in Monte Carlo data set k = 1, ...,K, the Bayes
decisions a∗1(xik) , the posterior mean estimates of µL(a∗1(xik),θ,xik) and µY (a∗1(xik),θ,xik),
and the 95 % credible intervals. Odds ratio φ was assumed known. We report the Monte
Carlo estimates of the sample-average of the bias B = (nK)−1∑ik µˆik − µik, where µˆik is the
posterior mean estimate of µ(a∗1(Xik),θ,xik) and µik its true value determined by (22); the width
ω = (nK)−1∑i,k uik − lik, where uik and lik the upper and lower limits of credible interval i in
data set k; the coverage probability of the credible intervals C = (nK)−1∑i,k 1{µik ∈ [lik, uik]};
and the accuracy of decision a∗1 with A = (nK)−1
∑
i,k 1{a∗1(xik) = aopt(xik)}.
4.4 Results
Table 3 compares the correctly specified logistic regression models (22) with uninformative
priors and q = 0 noise variables to BART with q = 5 for OTRmax loss (with φ = 1). In
Appendix B, we include results for the logistic regression model with q = 5 and BART with
q = 0. For the correctly specified logistic model (q = 0), we found a bias in posterior mean
estimates of expected loss and outcome under the OTR that increased at mild or no treatment
effect heterogeneity and decreased in larger samples. The direction of the bias was positive
in the sense that outcome probability was overestimated and loss was underestimated due to
optimism. Credible interval coverage probability increased with sample size, where CY reached
roughly 95% at n = 1000 in most cases and CL occasionally was slightly smaller. Interval width
decreased with sample size, as expected; however we also found a difference across selectivity
conditions λ, with λ = − log(3) causing greater average interval width than under λ = 1 and
λ = log(3). This finding illustrates the important role played by selectivity, which may cause
sparsity and thus wider intervals. Accuracy A of treatment decisions decreased with weaker
treatment effect heterogeneity and increased with sample size, ranging from 0.964 (n = 250,
λ = − log(3)) to 0.987 (n = 1000, λ = 0 and λ = log(3)) for strong heterogeneity and 0.823
to 0.947 for mild heterogeneity. Without heterogeneity, (β0 = β1 in (22)), accuracy is not
defined for OTRmax (14) and we used aopt = 0 as an arbitrary benchmark to compare Bayes
decisions against. About half of decisions were taken in favour of this benchmark (the others
being a∗ = 1), where higher sample size yielded A closer to 0.50 reflecting that Bayes decisions
are taken randomly. Note that interval coverage was not impacted despite this result and the
related optimism bias.
With q = 5 noise variables, the logistic model suffered substantially, inflating bias and
interval width strongly (Appendix B). Despite wider intervals, coverage was low even in large
samples (approx. 0.90) and unacceptably low in small samples. To the contrary, for BART with
q = 5 the optimism bias was only slightly higher than under the correctly specified logistic model
(Table 3). Furthermore, accuracy under strong heterogeneity was only slightly lower ranging
from 0.926 (n = 250, λ = log(3)) to 0.959 (n = 1000, λ = log(3)). Under mild heterogeneity
accuracy was still good ranging from 0.691 (n = 250, λ = log(3)) to 0.840 (n = 250, λ = 0);
larger samples yielded a clear gain in accuracy here. Furthermore, BART had conservative
coverage at 0.99 throughout conditions, where the correctly specified logistic regression model
partly had too liberal coverage. However, credible intervals were wider on average than under
the logistic model, emphasizing large samples are needed for precise inference with BART.
Compared to the logistic model with q = 5 (Appendix B), BART at q = 5 had smaller bias
12
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and interval width at much better coverage. BART also strongly profited from data without
noise variables in the set X (q = 0; Appendix B). Interval width was then reduced (slightly
wider than under the correctly specified logistic model), while coverage remained at high levels.
Bias was slightly smaller and almost competitive with the correctly specified logistic model.
Accuracy was increased throughout.
We repeated this analysis for a second loss function, OTR.25 (Table 4). Throughout con-
ditions, optimism bias under, both, the correctly specified model and BART was smaller. The
methods also yielded very comparable coverage and width of credible intervals as under OTR-
max loss. Likewise accuracy was similar for strong and mild treatment effect heterogeneity.
Without heterogeneity, the optimal decision aoptOTR.25 was 0, regardless of the value for X1 (for
OTR.25 loss function plots see Figure A1 in Appendix B). This decision was recovered with good
accuracy for both logistic regression and BART; as before larger samples yielded a substantial
increase in accuracy (e.g., see BART with λ = log(3)).
5 OTR for oropharynx cancer
In this section we develop OTR for oropharynx cancer. We first explain details of the data,
loss functions, and modelling. Subsequently, results on expected loss and survival probabilities
under three candidate treatment regimes are presented.
5.1 Data and model
Observational data on patients diagnosed with Oropharyngeal Squamous Cell Carcinoma (OP-
SCC) at VUmc Amsterdam, The Netherlands, were available (Nauta et al., 2018). We optimized
assignment of RT (W = 0) vs. CRT (W = 1) treatment using different loss functions. The pro-
portion of patients receiving CRT was 55.2%. We considered survival status at three years after
treatment (Y (0), Y (1)). Patient covariates (X) included age, gender, tumour T-stage (five cate-
gories, T1 to T4b), tumour N-stage (four categories, N0 to N3), alcohol use (unit years), smoking
(package years), co-morbidity assessment (three categories, Adult Co-morbidity Evaluation-27),
and human papillomavirus infection (HPV). The clinical decision for CRT (W = 1) considers
tumour stage, age, and co-morbidities. These confounders were observed in support of assump-
tion (2). To assess covariate overlap, we estimated propensity scores P (W = 1|xi; βˆ) for all
i = 1, ..., n, from logistic model P (W = 1|xi;β) = expit(xTi β) and compared the propensity
distributions in groups W = 0, 1 (Appendix C). To facilitate overlap, patients aged 75 years or
higher were omitted (n=277 after omission) and tumour stages N2 and N3 were merged.
We considered three loss functions (regimes) in the conditional parametrization (Table 1):
OTRmax with (L(1)00 , L
(0)
01 , L
(1)
10 , L
(1)
11 ) = (0, 1, 1, 0), OTR.25 with (0.25, 1, 1.25, 0.25), and OTR.50
with (0.50, 1, 1.50, 0.50). The coefficients L(1)00 and L
(1)
11 quantify loss due to unnecessary burden
that patients with equal survival outcomes under both treatments receive from CRT assignment.
These errors are penalised with 25% and 50% of the loss from a wrong treatment decision leading
to death (L(0)01 scaled at 1). Coefficient L
(1)
10 is set to 1.25 (1.50) to reflect the loss due to wrong
treatment by CRT and unnecessary burden simultaneously. We modelled the potential outcomes
using BART with prior settings as discussed in section 4. We multiply imputed missing data
on the alcohol (n = 3), comorbidity (n = 2), and HPV variables (n = 7) using predictive
mean matching with five imputed data sets. BART models of the potential outcomes were
fitted on each completed data set. This resulted in five posterior distributions of the marginal
probabilities (pi1+, pi+1) with 5× 103 draws respectively. Following Gelman et al. (2013), these
posterior distributions were pooled for inference.
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5.2 Results
We first held the partial association of potential outcomes fixed at φ0 = 1 and used posterior
mean decision rule a∗1 (7) to assess the OTR. We found that 60.3% of patients received CRT
under OTRmax loss, but only 13.4% under OTR.25 and 0.7% under OTR.50 caused by increased
penalization of unnecessary burden in these regimes. The empirical distribution of the posterior
probabilities for assigning CRT correctly, ρ(xi) in (8), is shown in Figure 2. The decision
boundary for a∗2 = 1 (9) at ρ = 0.5 is illustrated. The OTRmax probabilities at each quantile
were higher than for OTR.25 and OTR.50, reflecting that more patients benefit from CRT under
OTRmax loss. We carried out a sensitivity analysis for φ by evaluating all decisions again at the
conservative bounds φ = [exp(−3), exp(3)]. For a∗1, 4.7% (OTR.25) and 1.4% (OTR.50) of all
decisions changed between these bounds; these decisions are called sensitive to φ. The impact of
φ on ρ(xi) is illustrated by bounds in Figure 2. Only few bounds enclosed the decision boundary
at 0.5 demonstrating non-sensitivity of most decisions. In addition, we used black/grey coding
in Figure 2 to compare the posterior probabilities to treatments received (W ). At the left tail
of the distribution of ρ(X) under OTRmax more patients received RT (W = 0) than CRT;
similarly more patients at the right tail received CRT (W = 1) than RT. Averaged across the
sample, 60.3% (OTRmax), 51.6% (OTR.25), and 45.5% (OTR.50) received the same treatment
under optimal assignment (a∗1) and the one observed (W ). OTRmax had strongest overlap with
the observed regime, but there were still substantial differences in assignment strategies.
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Figure 2: Empirical quantile plots of posterior probabilities for correct CRT assignment at φ0 =
1 for different loss functions (regimes). A sensitivity analysis is carried out for log(φ) ∈ {−3, 3}.
The survival probabilities under the OTR, i.e. µY (a∗1(xi),θ,xi) in (11), were compared to
probabilities under the observed regime W , µY (wi,θ,xi) (Figure 3). A sensitivity analysis is
not needed for this estimand (section 3.2). At any quantile the distribution under OTRmax had
slightly higher value than under the observed regime W . Largest differences were present at
the lower tail suggesting most potential for survival probability optimization concerns patients
with small survival probabilities under both treatments (differences in survival probabilities
amount to 0.3). Uncertainty around posterior means is indicated by 95% credible intervals,
where we found lower probabilities had higher posterior uncertainty than higher probabilities.
For OTR.25 and OTR.50 uncertainty was similar but the gain in survival was nullified. This
reflects the objective of loss minimization instead of survival probability maximization. This
trade-off is further illustrated by comparing µY (a∗1(xi),θ,xi) to expected loss µL(a∗1(xi),θ,xi),
(4), in Figure 4. Expected loss of all regimes was lower than that of the observed regime and
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for OTR.25 and OTR.50 the reduction in loss relative to the observed regime was substantial.
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Figure 3: Mean posterior survival probabilities by OTR µY (a∗1(xi),θ,xi) as compared to the
observed regime µY (wi, θ,xi). 95% credible intervals given for µY (a∗1(xi),θ,xi). The figure
includes all n = 277 patients, i.e. also patients with sensitive decisions for which we fixed φ = 1.
An alternative is to omit these patients as shown in Appendix C with similar results.
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Figure 4: Mean posterior expected loss µL(a∗1(xi),θ,xi) under OTR (optimal regime) and the
observed regime µL(wi,θ,xi). Credible intervals given for OTR. Parameter uncertainty of φ
simulated by prior φ ∼ U(exp(−3), exp(3)).
There is additional uncertainty in posterior estimates of µL(a∗1(xi),θ,xi) due to sensitivity
of inference to association φ (section 3.2). Keeping decisions a∗1(xi) fixed at φ0 = 1, we assumed
a uniform prior on φ ∼ U(exp(−3), exp(3)) and integrated φ out during the estimation phase.
The interval width in Figure 4 was thereby increased compared to e.g. φ = 1 (conditional
independence of potential outcomes), in particular by 7.0% (OTRmax), 5.4% (OTR.25), and
5.9% (OTR.50). These results demonstrate that intervals are robust to strong prior uncertainty
about φ.
To summarize results, we average survival probabilities and expected losses (Table 5), where
we define U(a) := n−1∑i µˆ(ai,θ,xi), with µˆ the posterior mean estimates of µY or µL (shown
in Figures 3 and 4); furthermore, W¯ = n−1∑iWi the sample proportion of patients receiving
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CRT under observed treatment assignment W and a¯∗1 = n−1
∑
i a
∗
1i(xi) the sample proportion
of patients receiving CRT under the OTR. The average expected loss under the observed regime
increased strongly from OTRmax to OTR.50 loss functions, but remained on low levels under the
optimal regime a∗1. Average survival probability under W was 72.8%. OTRmax loss increased
average survival probability to 75.9%, whereas OTR.25 and OTR.50 had averaged probabilities
only slightly below those of the observed regime. However, CRT assignment could be strongly
reduced, in particular below the observed regime (55.2%). In conclusion, the decision which loss
function and regime are ’best’ remains subjective. However, a good candidate is OTR.25 which
reduced patient burden by strongly reducing CRT assignment by four times (55.2 to 13.4%)
without lowering the average survival probability much under that of the observed regime (72.8
vs. 72.5%; emphasis added in Table 5).
Table 5: Sample-averaged posterior mean estimates of expected losses and survival probabilities
under the OTR (a∗1) and observed regime (W ) and the proportion of patients assigned to CRT.
Average loss Average survival prob. Prop. assigned CRT
Loss function UL(W ) UL(a∗1) UY (W ) UY (a∗1) W¯ a¯∗1
OTRmax 0.148 0.118 0.728 0.759 0.552 0.603
OTR.25 0.259 0.173 0.728 0.725 0.552 0.134
OTR.50 0.370 0.181 0.728 0.697 0.552 0.007
6 Discussion
We suggested a decision theoretical framework for estimating optimal treatment regimes (OTR)
based on a loss function specified on the bivariate distribution of dichotomous potential out-
comes. Our approach distinguishes expected patient loss from expected outcomes (e.g., survival
probabilities), so that the effects of minimized loss can be compared and traded off against the
expected outcomes under an OTR (Table 5). Furthermore, the particular loss parametriza-
tion can be flexibly tailored to the application, where we advocated using the conditional
parametrization which is closely aligned to clinical decision making. Importantly, it allows
penalizing unnecessary treatment burden (besides treatment failure), which is a central con-
sideration in clinical practice. In an application to oropharyngeal cancer (OPSCC), we could
achieve a fourfold reduction in burdensome chemotherapy (CRT) assignment without lowering
average survival probabilities below the level of the observed regime. Posterior probabilities for
treatment assignment as well as credible intervals and posterior mean estimates for expected
loss and outcomes under an OTR are strongly informative measures that are useful to support
clinicians in decision making. For the OPSCC data, uncertainty in expected loss and survival
was larger at the lower tail of the distributions (Figures 3b and 4b), but posterior certainty
was high that radiotherapy without chemotherapy was the optimal strategy for many patients
(Figure 2b).
Furthermore, we developed Bayesian OTR estimation methodology assuming ignorable
treatment assignment. An advantage of our approach is that it relies on two marginal Bayesian
models of the potential outcomes, which allows applying standard Bayesian techniques including
model updating, model and variable selection, and inclusion of prior information. In practice,
however, the functional relationship between patient covariates and the potential outcomes is
often unknown. Bayesian statistical and machine learning may then facilitate functional ap-
proximation, where we evaluated and applied Bayesian additive regression trees, BART. Our
estimation approach is related to variants suggested by Zajonc (2012) and Murray et al. (2017)
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who use the posterior predictive distribution in the context of dynamic regimes, whereas we base
inference on the posterior distribution of the conditional marginal probabilities of the potential
outcomes and a prior assumption on their partial association. An important assumption of our
approach is ignorable treatment assignment requiring that all confounders are observed. Thor-
ough planning using expert knowledge is essential to have data on the required confounders.
For the case of the OPSCC data, all known causes of CRT assignment, by expert knowledge
and treatment protocols, were observed in support of the assumption.
In simulations we found an optimism bias of point estimates under many conditions where
we varied loss functions, treatment assignment mechanisms, treatment effect heterogeneity, and
sample size. In particular, the direction of bias of expected loss was negative (and positive
for outcomes) in small samples with low or no heterogeneity between expected losses. Bias
and interval width decreased and decision accuracy increased substantially in larger samples.
Frequentist interval coverage probabilities were nevertheless at nominal level for large samples
in the Bayesian logistic model, and conservative for BART, even in small samples. Nevertheless,
large samples appear desirable to control optimism bias and variance, needed in particular for
BART. Replication of our findings on the optimal OPSCC regime, based on n = 277, in larger
samples is therefore desirable.
Several further paths for future research are worth noting. Our approach may be adapted
to let loss functions depend on patient characteristics or preferences, which could broaden its
usefulness for personalized medicine. Furthermore, it is desirable to extend the approach to loss
functions and estimation for time-to-event (survival) outcomes and more than two treatments.
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Appendix A Proofs
Proof of Theorem 1. The coverage of I(a∗) is
P (µL(a∗,θ0,x) ∈ I(a∗)) = P (µL(1,θ0,x) ∈ I(1), a∗ = 1) + P (µL(0,θ0,x) ∈ I(0), a∗ = 0)
≥ P (a∗ = 1)− α+ P (a∗ = 0)− α = 1− 2α.
The remainder of this section is devoted to the proof of Theorem 2. We consider (non-
Bayesian) confidence intervals and prove Theorem 3 below. From this theorem we immediately
obtain Theorem 2.
Let (X,Y ) be a two-dimensional random vector having the bivariate normal distribution
with unknown mean (µ, ν) and positive-definite covariance matrix(
σ2 ρστ
ρστ τ2
)
,
with σ2 and τ2 known. The classical confidence intervals for µ and ν with coverage 1 − α are
given by
[X − σξ1−α/2, X + σξ1−α/2], [Y − τξ1−α/2, Y + τξ1−α/2], (24)
with ξ1−α/2 the (1−α/2) quantile of the standard normal distribution. We now define a decision-
based confidence interval I by selecting one of the two intervals based on the outcome of (X,Y ),
as follows:
I =
{
[X − σξ1−α/2, X + σξ1−α/2], if X ≤ Y,
[Y − τξ1−α/2, Y + τξ1−α/2], if X > Y.
I.e. we select the interval with the smallest mean. We define the coverage of I as P (T ∈ I),
with
T =
{
µ, if X ≤ Y,
ν, if X > Y.
As an appetizer, suppose µ = ν = 0, σ2 = τ2 = 1 and ρ = 0. Then
I = [min{X,Y } − ξ1−α/2,min{X,Y }+ ξ1−α/2]
and the coverage of I is
P (0 ∈ I) = P (0 < min{X,Y }+ ξ1−α/2)− P (0 < min{X,Y } − ξ1−α/2)
= (1− α/2)2 − (α/2)2 = 1− α.
Hence the interval I has a negative bias, but nevertheless the coverage is 1− α.
Theorem 3. The coverage of I is
(i) equal to 1− α, if µ = ν or σ2 = τ2,
(ii) strictly between 1− α and 1− 12α, if µ > ν and σ2 < τ2,
(iii) strictly between 1− 32α and 1− α, if µ > ν and σ2 > τ2.
Before proceeding to the proof of Theorem 3, we show how Theorem 2 follows from it. By
the assumptions in Theorem 2, the credible intervals I(1), I(0) are of the form (24). Indeed, X,Y
represent the means of the intervals, which by assumption have the bivariate normal distribution
with variances σ2 = σ2(1) and τ2 = σ2(0). By normality of the means, by the assumption that
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the widths of the intervals are constant, and because we assumed the coverage of I(1), I(0) to
be symmetric in the sense of (21), we must have that µ = µL(1,θ0,x), ν = µL(0,θ0,x) and
I(1) = [X − σξ1−α/2, X + σξ1−α/2], I(0) = [Y − τξ1−α/2, Y + τξ1−α/2].
This proves Theorem 2; it remains to prove Theorem 3.
Proof of Theorem 3. We write ξ = ξ1−α/2 and denote
x˜ = x− µ
σ
, y˜ = y − ν
τ
.
We can write the coverage of I as
P (X > Y, ν ∈ [Y − τξ, Y + τξ])
+ P (X < Y, µ ∈ [X − σξ,X + σξ])
= P (X > Y, X˜ > ξ, |Y˜ | < ξ) (25)
+ P (X > Y, |X˜| < ξ, |Y˜ | < ξ) (26)
+ P (X > Y, X˜ < −ξ, |Y˜ | < ξ) (27)
+ P (X < Y, |X˜| < ξ, Y˜ > ξ) (28)
+ P (X < Y, |X˜| < ξ, |Y˜ | < ξ) (29)
+ P (X < Y, |X˜| < ξ, Y˜ < −ξ). (30)
Note that we must have (27) = 0 or (30) = 0, which can be easily seen from a two-dimensional
plot of y˜ against x˜. This implies that the coverage of I is less than P (X˜ > −ξ) or P (Y˜ > −ξ),
respectively, which gives the upper bound of statement (ii) of the theorem. Furthermore,
(26) + (29) = P (|X˜| < ξ, |Y˜ | < ξ)
and
(25) = P (X˜ > ξ, |Y˜ | < ξ) or (28) = P (|X˜| < ξ, Y˜ > ξ).
Therefore, the coverage of I is greater than
1− P (X˜ < −ξ)− P (|Y˜ | > ξ) or 1− P (|X˜| > ξ)− P (Y˜ < −ξ),
respectively. This yields the lower bound of statement (iii).
Using the decomposition (25)–(30), we will prove that the coverage of I is (i) equal to, (ii)
greater than, or (iii) less than
P (X˜ > −ξ, Y˜ > −ξ)− P (X˜ > ξ, Y˜ > ξ), (31)
if (i) µ = ν or σ2 = τ2, (ii) µ > ν and σ2 < τ2, or (iii) µ > ν and σ2 > τ2, respectively. The
theorem then follows from the fact that (31) equals
1− P (X˜ < −ξ)− P (Y˜ < −ξ)
+ P (X˜ < −ξ, Y˜ < −ξ)− P (X˜ > ξ, Y˜ > ξ)
= 1− α/2− α/2 + 0
= 1− α,
where we use the fact that (X˜, Y˜ ) has the same distribution as (−X˜,−Y˜ ). It remains to prove
statement (31); we split the proof in four cases.
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Case 1. Suppose µ ≥ ν, σ2 ≤ τ2 and
µ− ν ≤ (τ − σ)ξ. (32)
We will evaluate each of the terms (25)–(30), and show that their sum is equal to (31) if µ = ν,
and greater than (31) if µ > ν. Obviously,
(26) + (29) = P (|X˜| < ξ, |Y˜ | < ξ). (33)
Furthermore, if x˜ < ξ and y˜ > ξ then, by assumption (32),
y − x = τ y˜ + ν − σx˜− µ > (τ − σ)ξ − (µ− ν) ≥ 0,
which implies that
(28) = P (|X˜| < ξ, Y˜ > ξ). (34)
Similarly, if x˜ > −ξ and y˜ < −ξ then
y − x = τ y˜ + ν − σx˜− µ < −(τ − σ)ξ − (µ− ν) ≤ 0,
which gives
(30) = 0. (35)
Using the fact that (X˜, Y˜ ) has the same distribution as (−X˜,−Y˜ ), we obtain
(27) = P (X˜ > (τ/σ)Y˜ − (µ− ν)/σ, X˜ < −ξ, |Y˜ | < ξ)
≥ P (X˜ > (τ/σ)Y˜ + (µ− ν)/σ, X˜ < −ξ, |Y˜ | < ξ)
= P (−X˜ > (τ/σ)(−Y˜ ) + (µ− ν)/σ,−X˜ < −ξ, | − Y˜ | < ξ)
= P (X < Y, X˜ > ξ, |Y˜ | < ξ),
where the inequality is in fact an equality if and only if µ = ν. It follows that
(25) + (27) ≥ P (X˜ > ξ, |Y˜ | < ξ). (36)
Combining (33), (34), (35) and (36) yields that the coverage of I is greater than or equal to
(31), with equality if and only if µ = ν.
Case 2. Suppose µ ≥ ν, σ2 ≤ τ2 and µ− ν ≥ (τ − σ)ξ. To give a bound on (27), consider
the two lines
y˜ = σ
τ
x˜+ µ− ν
τ
, (37)
y˜ = τ
σ
x˜+ µ− ν
σ
. (38)
The two lines intersect at the point (−(µ − ν)/(σ + τ), (µ − ν)/(σ + τ)), which is outside the
region x˜ < −ξ, y˜ < ξ. If σ2 < τ2 then the slope of line (38) is greater than the slope of line
(37). Therefore, if
x˜ < −ξ, y˜ < ξ, y˜ < τ
σ
x˜+ µ− ν
σ
,
then we must have y˜ < (σ/τ)x˜+ (µ− ν)/τ . This implies
(27) = P (Y˜ < (σ/τ)X˜ + (µ− ν)/τ, X˜ < −ξ, |Y˜ | < ξ)
≥ P (Y˜ < (τ/σ)X˜ + (µ− ν)/σ, X˜ < −ξ, |Y˜ | < ξ), (39)
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with equality if and only if σ2 = τ2. Since (X˜, Y˜ ) has the same distribution as (−Y˜ ,−X˜), the
right hand side of (39) is equal to
P (−X˜ < (τ/σ)(−Y˜ ) + (µ− ν)/σ,−Y˜ < −ξ, | − X˜| < ξ)
= P (X > Y, Y˜ > ξ, |X˜| < ξ).
It follows that
(27) + (28) ≥ P (|X˜| < ξ, Y˜ > ξ),
with equality if and only if σ2 = τ2. In a similar way as in Case 1 we can deduce from this that
the coverage of I is greater than or equal to (31), with equality if and only if σ2 = τ2.
Case 3. Suppose µ > ν, σ2 > τ2 and µ− ν ≤ (σ− τ)ξ. Using the fact that (X˜, Y˜ ) has the
same distribution as (−X˜,−Y˜ ), we see that
(30) = P (X˜ < (τ/σ)Y˜ − (µ− ν)/σ, |X˜| < ξ, Y˜ < −ξ)
< P (X˜ < (τ/σ)Y˜ + (µ− ν)/σ, |X˜| < ξ, Y˜ < −ξ)
= P (−X˜ < (τ/σ)(−Y˜ ) + (µ− ν)/σ, | − X˜| < ξ,−Y˜ < −ξ)
= P (X > Y, |X˜| < ξ, Y˜ > ξ).
It follows that
(28) + (30) < P (|X˜| < ξ, Y˜ > ξ).
Similar to the proof of Case 1 we obtain that the coverage of I is less than (31).
Case 4. Suppose µ > ν, σ2 > τ2 and µ− ν ≥ (σ− τ)ξ. Then the coverage of I is less than
(31). The proof is similar to the proof of Case 2 and we omit it.
In the proof of Theorem 3 we have not used the specific shape of the normal distribution.
The statement of the theorem holds more generally if (X,Y ) has a continuous distribution with
unknown mean (µ, ν) and known variances σ2, τ2 such that, for all µ and ν, the distribution of
((X−µ)/σ, (Y − ν)/τ) does not depend on µ, ν and is invariant under the reflections f1(u, v) =
(v, u) and f2(u, v) = (−v,−u).
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Appendix B Supplemental material to simulation study
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Figure A1: True loss functions specified for the simulation by parametrizations OTRmax and
OTR.25 and treatment effect heterogeneity (het.). The condition ’OTRmax, no het.’ has no
unique decision boundary (no treatment is optimal). The condition ’OTR.25, no het.’ has no
optimal decision boundary and a = 0 is optimal for any X1.
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Appendix C Supplemental material to oropharynx OTR study
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Figure A2: Mean posterior survival probabilities by OTR µY (a∗1(xi), θ,xi) as compared to the
observed regime µY (wi, θ,xi). 95% credible intervals given for µY (a∗1(xi), θ,xi). Patients with
non-robust decisions omitted.
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(c) OTR.50
Figure A3: Mean posterior expected loss µL(a∗1(xi), θ,xi) under OTR (optimal regime) and the
observed regime µL(wi, θ,xi). Credible intervals given for OTR. Parameter uncertainty of φ
simulated by prior φ ∼ U(exp(−3), exp(3)). Patients with non-robust decisions omitted.
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Figure A4: Logit propensities by treatments received. Propensities were estimated using a
logistic treatment assignment model. The distributions demonstrate overlap in support of the
overlap assumption under the Rubin Causal Model.
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